Crenolanib Besylate

苯磺酸克诺拉尼

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameCrenolanib Besylate
Drug Alias NameCrenolanibum克瑞拉尼Crenolanib克拉尼布克瑞兰尼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsPlatelet-derived growth factor receptor beta inhibitors
TargetsPlatelet-derived growth factor receptor betaTyrosine-protein kinase receptor FLT3Platelet-derived growth factor receptor alpha
Therapy Area/IndicationsGliomaGastrointestinal Stromal TumorsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesArog Pharmaceuticals IncPatheon IncJilai'An (Shanghai) Biological Technology Co Ltd
Inactive CompaniesUlm University
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsGliomaGastrointestinal Stromal Tumors

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG